Clinical Trial Update: ADCC Mediated B-Cell dEpletion and BAFF-R Blockade [Phase 2, Phase 3]

View source ↗

Summary

A Novartis-sponsored clinical trial evaluating ADCC-mediated B-cell depletion and BAFF-R blockade for autoimmune hepatitis has completed Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hepatitis

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Autoimmune Hepatitis | Phase 2, Phase 3 | Status: COMPLETED